Shares of Genzyme were buoyed slightly by the news that Mozobil hit primary and secondary goals in a late-stage trial for non-Hodgkin's lymphoma. The drug spurs the release of bone marrow stem cells into the blood so that they can be collected and used in a transplant. About six in 10 of the patients in the study demonstrated an increased stem cell count while 87 percent produced the necessary number of stem cells needed for a transplant. Applications for U.S. and European marketing approval is now expected in the first half of next year. Genzyme gained Mozobil when it bought out AnorMED [1] earlier this year.
- read the release [2] for more
- here's the AP report [3] on the trial data
Related Articles:
Genzyme wins bidding war for AnorMED. Report [1]
Genzyme to pursue rare hostile biotech bid. Report [4]
Millennium to buy AnorMed for $515M. Report [5]
Genzyme boosts AnorMed bid to $580M. Report [6]
Links:
[1] http://www.fiercebiotech.com/story/genzyme-wins-bidding-war-for-anormed/2006-10-17
[2] http://www.fiercebiotech.com/node/7696
[3] http://www.forbes.com/feeds/ap/2007/07/19/ap3931568.html
[4] http://www.fiercebiotech.com/story/genzyme-to-pursue-rare-hostile-biotech-bid/2006-08-31
[5] http://www.fiercebiotech.com/story/millennium-to-buy-anormed-for-515m/2006-09-27
[6] http://www.fiercebiotech.com/story/genzyme-boosts-anormed-bid-to-580m/2006-10-10